(Q36641310)

15 August 2017

Markers of bone turnover for the management of patients with bone metastases from prostate cancer (English)

1 reference

15 August 2017

1 reference

Garnero P

1

1 reference

15 August 2017

Buchs N

2

1 reference

15 August 2017

Zekri J

3

1 reference

15 August 2017

Rizzoli R

4

1 reference

15 August 2017

Coleman RE

5

1 reference

15 August 2017

Delmas PD

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

82

1 reference

15 August 2017

4

1 reference

15 August 2017

858-864

1 reference

https://scigraph.springernature.com/pub.10.1054/bjoc.1999.1012

15 August 2017

0 references

cites work

Bisphosphonates in prostate carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Dissociation of bone formation markers in bone metastasis of prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Metabolic effects of pamidronate in patients with metastatic bone disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Treatment of painful prostatic bone metastases with oral etidronate disodium

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Use of bisphosphonates in cancer patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2374389

Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone

4 December 2018

1 reference

12 December 2020

Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen

1 reference

12 December 2020

Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone

1 reference

12 December 2020

The diagnostic value of urinary Crosslaps and serum alkaline phosphatase in patients with prostate cancer

1 reference

12 December 2020

Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma

1 reference

12 December 2020

Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease

1 reference

12 December 2020

Elimination of alkaline phosphatases from circulation by the galactose receptor. Different isoforms are cleared at various rates

1 reference

12 December 2020

Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton

1 reference

12 December 2020

Monitoring of bone metastases

1 reference

12 December 2020

Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen

1 reference

12 December 2020

Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease

1 reference

12 December 2020

Hepatic clearance of rat plasma intestinal alkaline phosphatase

1 reference

12 December 2020

Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone

1 reference

12 December 2020

Generalised increase in bone resorption in carcinoma of the prostate

1 reference

12 December 2020

Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease

1 reference

12 December 2020

Morphometric evidence for bone resorption and replacement in prostate cancer

1 reference

12 December 2020

Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay

1 reference

12 December 2020

Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation

1 reference

12 December 2020

The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy

1 reference

12 December 2020

Immunoassay for quantifying type I collagen degradation products in urine evaluated

1 reference

12 December 2020

Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment

1 reference

12 December 2020

Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer

1 reference

12 December 2020

Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer

1 reference

12 December 2020

Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption

1 reference

12 December 2020

Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer

1 reference

12 December 2020

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

1 reference

12 December 2020

Correlation between bone metabolic markers and bone scan in prostatic cancer

1 reference

12 December 2020

Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region

1 reference

12 December 2020

The flare phenomenon on radionuclide bone scan in metastatic prostate cancer

1 reference

12 December 2020

Identifiers

DOI

10.1054/BJOC.1999.1012

1 reference

Dimensions Publication ID

15 August 2017

1048823579

0 references

Fatcat ID

release_p25552owkffurfknj3zd2cimqq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/p25552owkffurfknj3zd2cimqq

24 November 2022

mapped directly with Wikidata item

1 reference

15 August 2017

PubMed publication ID

10732759

1 reference